NFE2L2 and optic neuritis: Dimethyl fumarate, a Nrf2 activator that has been licensed for the treatment of relapsing-remitting multiple sclerosis in the US since 2013, has shown promising results in experimental autoimmune encephalomyelitis (EAE) models, reducing the severity and relapses of optic neuritis and preserving RGCs from cell death [444].